Long‐term follow‐up of children with high‐risk neuroblastoma: The ENSG5 trial experience
Pediatric Blood & Cancer2012Vol. 60(7), pp. 1135–1140
Citations Over TimeTop 12% of 2012 papers
Lucas Moreno, Sucheta Vaidya, CR Pinkerton, Ian Lewis, John Imeson, David Machin, Andrew D.J. Pearson, on behalf of the European Neuroblastoma Study Group and the Children's Cancer and Leukaemia Group (CCLG) (formerly UKCCSG)
Abstract
This study analyzed a wide cohort of high-risk neuroblastoma survivors from a multi-institutional randomized trial and established the profile of long-term toxicity within the setting of an international clinical trial.
Related Papers
- → Randomized Multicenter Trial of Hyperthermic Isolated Limb Perfusion With Melphalan Alone Compared With Melphalan Plus Tumor Necrosis Factor: American College of Surgeons Oncology Group Trial Z0020(2006)221 cited
- → Melphalan uptake, hyperthermic synergism and drug resistance in a human cell culture model for the isolated limb perfusion of melanoma(1994)45 cited
- → Factors influencing the chemosensitization of melphalan by misonidazole(1985)20 cited
- [Conservative therapy for retinoblastoma--effect of melphalan on in vitro electroretinogram].(1994)